Incyte | INCY - Bienes





Bienes Cambio Fecha
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agenus USD 172.69M 13.76M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amgen USD 95.64B 3.14B 2026-06
BioCryst Pharmaceuticals USD 557.85M 92.8M 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Exelixis USD 2.49B 99.36M 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
Incyte USD 7.87B 533.53M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06